Nurix Therapeutics, Inc. (NRIX) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 09/15/23
Wall Street Analysts Think Nurix Therapeutics, Inc. (NRIX) Could Surge 215.32%: Read This Before Placing a BetZacks Investment Research • 09/15/23
Nurix Therapeutics, Inc. (NRIX) Soars 8.3%: Is Further Upside Left in the Stock?Zacks Investment Research • 09/08/23
Wall Street Analysts Believe Nurix Therapeutics, Inc. (NRIX) Could Rally 195.93%: Here's is How to TradeZacks Investment Research • 07/24/23
Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 07/13/23
Nurix Therapeutics Reports Second Quarter Fiscal 2023 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 07/13/23
Nurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma IndicationsGlobeNewsWire • 06/14/23
Does Nurix Therapeutics, Inc. (NRIX) Have the Potential to Rally 192.09% as Wall Street Analysts Expect?Zacks Investment Research • 05/24/23
Nurix Therapeutics to Participate in the 2023 RBC Capital Markets Global Healthcare ConferenceGlobeNewsWire • 05/09/23
Wall Street Analysts Predict a 233.33% Upside in Nurix Therapeutics, Inc. (NRIX): Here's What You Should KnowZacks Investment Research • 05/04/23
How Much Upside is Left in Nurix Therapeutics, Inc. (NRIX)? Wall Street Analysts Think 134.94%Zacks Investment Research • 04/18/23
Nurix Therapeutics Presents Data at the American Association for Cancer Research (AACR) Annual Meeting Highlighting Activity of its BTK Targeted Protein Degraders, NX-2127 and NX-5948, against a Broad Range of BTKi Resistance MutationsGlobeNewsWire • 04/17/23
Nurix Therapeutics Reports First Quarter Fiscal 2023 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 04/13/23
Nurix Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/11/23
Will Nurix Therapeutics, Inc. (NRIX) Report Negative Q1 Earnings? What You Should KnowZacks Investment Research • 03/30/23
Strength Seen in Nurix Therapeutics, Inc. (NRIX): Can Its 5.7% Jump Turn into More Strength?Zacks Investment Research • 03/21/23
Gilead Exercises Option to License Nurix's IRAK4 Targeted Protein Degrader Development Candidate, NX-0479Business Wire • 03/20/23
Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2023 Annual MeetingGlobeNewsWire • 03/14/23
Nurix Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare ConferenceGlobeNewsWire • 03/06/23
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 02/09/23
Bears are Losing Control Over Nurix Therapeutics, Inc. (NRIX), Here's Why It's a 'Buy' NowZacks Investment Research • 01/09/23